Past, Present and Future Perspective of Application of Nanobiotechnology in Pharmacology and Innovative Therapeutics

Main Article Content

Larry L Mweetwa Tiro Mampane Thatoyaone J Kenaope Bonang Mosala Kenneth Pule Gerald Juma Obure Getrude Mothibe


Nanobiotechnology is a multi-strategic approach that engineers biological components (atoms and molecules) at the nanoscales. The concept was introduced as an effective alternative with drug delivery and targeting properties. Nanobiotechnology has several applications in cancerous disease, autoimmune, inflammation, infectious, and viral diseases, and for the management of COVID-19. Nanoparticles have biomimetic properties, encapsulation, and safety formulation of drugs, and all these properties give them an advantage over conventional drug strategies. Nanobiotechnology research is currently progressive and needs extensive exploration and understanding for its potential use in future innovations. The present review studied the concept of nanobiotechnology, its origin, mechanism of drug delivery and targeting, applications, and future perspective in pharmacology and innovation to decipher its role in future advanced research.

Article Details

How to Cite
MWEETWA, Larry L et al. Past, Present and Future Perspective of Application of Nanobiotechnology in Pharmacology and Innovative Therapeutics. Medical Research Archives, [S.l.], v. 10, n. 3, mar. 2022. ISSN 2375-1924. Available at: <>. Date accessed: 24 may 2024. doi:
Research Articles


1. Balaji, S. Nanobiotechnology. MJP Publisher. 2019.,+S.+(2019).+Nanobiotechnology.+MJP+Publisher.&ots=q4FTLtma1C&sig=iJ3k2-DItsFqyVWHvLEEdgBW3Xk. [Accessed February 10, 2022]
2. Qi, B., Wang, C., Ding, J., & Tao, W. Applications of Nanobiotechnology in Pharmacology. Frontiers in Pharmacology. 2019; 10, 1451.
3. Jain, K. K. Nanomedicine: application of nanobiotechnology in medical practice. Medical Principles and Practice. 2008; 17(2), 89-101.
4. Sah, S. K., Kaur, A., & Wani, S. H. Nanobiotechnology: changing horizons of science. Biolife. 2014; 2(3), 905-916.
5. Demetzos, C. Pharmaceutical Nanotechnology. Springer Singapore: Singapore; 2016. 1-224.
6. Maravajhala, V., Papishetty, S., & Bandlapalli, S. Nanotechnology in the development of drug delivery system. International Journal of Pharmaceutical Sciences and Research. 2012; 3(1), 84.
7. Witika, B. A., & Walker, R. B. Development, manufacture, and characterization of niosomes for the delivery for nevirapine. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2019; 74(2), 91-96.
8. Witika, B. A., Smith, V. J., & Walker, R. B. Top-down synthesis of a lamivudine-zidovudine nano co-crystal. Crystals. 2021; 11(1), 33.
9. Khan, I., Khan, M., Umar, M. N., & Oh, D. H. Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnology. 2015; 9(6), 396-400. 10.1049/iet-nbt.2014.0062
10. Ulku, Y., & Burcu, G. B. The importance of nanotechnology and drug carrier systems in pharmacology. GSC Biological and Pharmaceutical Sciences. 2020; 10(2), 014-023.
11. Bazak, R., Houri, M., El Achy, S., Hussein, W., & Refaat, T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Molecular and clinical oncology. 2014; 2(6), 904-908.
12. Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics. 2006; 5(8), 1909-1917. 10.1158/1535-7163.MCT-06-0141
13. Witika, B. A., Makoni, P. A., Mweetwa, L. L., Ntemi, P. V., Chikukwa, M. T., Matafwali, S. K., ... & Walker, R. B. Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment. Molecules. 2020; 25(24), 5952.
14. Roy, B., Dhillon, J. K., Habib, N., & Pugazhandhi, B. Global variants of COVID-19: Current understanding. Journal of Biomedical Sciences. 2021; 8(1), 8-11.
15. Fatima, U., Rizvi, S. S. A., Raina, N., Fatima, S., Rahman, S., Kamal, M. A., & Hassan, M. Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Current pharmaceutical design. 2021; 27(41), 4223-4231.
16. Cavalcanti, I. D. L., & Nogueira, M. C. D. B. L. Pharmaceutical nanotechnology: which products have been designed against COVID-19? Journal of Nanoparticle Research. 2020; 22(9), 1-11.
17. Moradiya, M. A., Khiriya, P. K., Khare, P. S., & Markna, J. H. (2021). Nanotechnology in Battle against CoViD-19: The Prevention, Diagnosis, and Treatment. Letters in Applied NanoBiosciences. 2021; 10(4), 2637-2645.
18. Yayehrad, A. T., Siraj, E. A., Wondie, G. B., Alemie, A. A., Derseh, M. T., & Ambaye, A. S. Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. International Journal of Nanomedicine. 2021; 16, 5713-5743.
19. Ramakrishnan, S. G., Robert, B., Salim, A., Ananthan, P., Sivaramakrishnan, M., Subramaniam, S., ... & Arasu, M. V. Nanotechnology-based solutions to combat zoonotic viruses with special attention to SARS, MERS, and COVID 19: Detection, protection, and medication. Microbial Pathogenesis. 2021; 159, 105133.
20. Sim, S., & Wong, N. K. Nanotechnology and its use in imaging and drug delivery. Biomedical Reports. 2021; 14(5), 1-9.
21. Nehra, M., Uthappa, U. T., Kumar, V., Kumar, R., Dixit, C., Dilbaghi, N., ... & Kaushik, A. Nanobiotechnology-assisted therapies to manage brain cancer in a personalized manner. Journal of Controlled Release. 2021; 338, 224-243.
22. Alizadeh, N., & Salimi, A. Multienzymes activity of metals and metal oxide nanomaterials: applications from biotechnology to medicine and environmental engineering. Journal of Nanobiotechnology. (2021); 19(1), 1-31.
23. Chatterjee, P., & Kumar, S. Current developments in nanotechnology for cancer treatment. Materials Today: Proceedings. 2022; 48, 1754-1758.
24. Wang, J., & Cui, H. Nanostructure-based theranostic systems. Theranostics. 2016; 6(9), 1274.
25. World Health Organization. WHO Report on Global Surveillance of Epidemic prone Infectious Diseases: Types of Surveillance; 2020.
26. Couvreur, P., & Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharmaceutical Research. 2006; 23(7), 1417-1450. 10.1007/s11095-006-0284-8
27. Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. Nanotechnology approaches for global infectious diseases. Nature Nanotechnology. 2021; 16(4), 369-384.
28. Saklayen, M. G. The global epidemic of the metabolic syndrome. Current hypertension reports. 2018; 20(2), 1-8.
29. Guo, H. H., Feng, C. L., Zhang, W. X., Luo, Z. G., Zhang, H. J., Zhang, T. T., ... & Jiang, J. D. Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. Nature Communications. 2019; 10(1), 1-16.
30. Jain, K. K. Synthetic biology and personalized medicine. Medical Principles and Practice. 2013; 22(3), 209-219.
31. Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E., Serda, R. E., Grattoni, A., ... & Ferrari, M. Enabling individualized therapy through nanotechnology. Pharmacological Research. 2010; 62(2), 57-89.
32. Bahadori, E., Farjami, Z., Rezayi, M., Lngari, H., Darroudi, M., Avan, A., & Ghayour-Mobarhan, M. Recent advances in nanotechnology for the treatment of the metabolic syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(2), 1561-1568.
33. Re, F., Gregori, M., & Masserini, M. Nanotechnology for neurodegenerative disorders. Maturitas. 2012; 73(1), 45-51.
34. Nirale, P., Paul, A., & Yadav, K. S. Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson’s, and Prion's. Life sciences. 2020; 245, 117394.
35. Kumar, R., Aadil, K. R., Mondal, K., Mishra, Y. K., Oupicky, D., Ramakrishna, S., & Kaushik, A. Neurodegenerative disorders management: state-of-art and prospects of nanobiotechnology. Critical Reviews in Biotechnology. 2021; 1-33.
36. Couvreur, P., Gref, R., Andrieux, K., & Malvy, C. Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases. Progress in Solid State Chemistry. 2006; 34(2-4), 231-235.
37. Cho, J. H., & Feldman, M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nature Medicine. 2015; 21(7), 730-738.
38. Gharagozloo, M., Majewski, S., & Foldvari, M. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction. Nanomedicine: Nanotechnology, Biology and Medicine. 2015; 11(4), 1003-1018.
39. Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. Biological drug, and drug delivery-mediated immunotherapy. Acta Pharmaceutica Sinica B. 2021; 11(4), 941-960.
40. Fakruddin, M., Hossain, Z., & Afroz, H. (2012). Prospects and applications of nanobiotechnology: a medical perspective. Journal of Nanobiotechnology, 10(1), 1-8.
41. Zhu, C., Zhang, S., Song, C., Zhang, Y., Ling, Q., Hoffmann, P. R., ... & Huang, Z. Selenium nanoparticles decorated with Ulva lactuca polysaccharide potentially attenuate colitis by inhibiting NF-κB mediated hyper inflammation. Journal of Nanobiotechnology. 2017; 15(1), 1-15. 10.1186/s12951-017-0252-y
42. Brusini, R., Varna, M., & Couvreur, P. Advanced nanomedicines for the treatment of inflammatory diseases. Advanced Drug Delivery Reviews. 2020; 157, 161–178.
43. Tan, Q., He, L., Meng, X., Wang, W., Pan, H., Yin, W., ... & Shan, H. Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. Journal of Nanobiotechnology. 2021; 19(1), 1-16.
44. Bonilla, L., Esteruelas, G., Ettcheto, M., Espina, M., García, M. L., Camins, A., ... & Sánchez‐López, E. Biodegradable nanoparticles for the treatment of epilepsy: from current advances to future challenges. Epilepsia Open. 2021;00: 1-12.
45. Mukarram, M., Naeem, M., Aftab, T., & Khan, M. M. A. Chitin, chitosan, and chitooligosaccharides: recent advances and future perspectives. Radiation-Processed Polysaccharides. 2022; 339-353.
46. Vizirianakis, I. S., Miliotou, A. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics. Expert Review of Precision Medicine and Drug Development. 2019; 4(3), 139-151.
47. Shintaro, H., Mona, U., Kumiko, T., Rie, H., Yuki, T., Masaaki, M., & Toshio, H. (2020). How Covid-19 induces cytokine storm with high mortality. Inflammation and Regeneration. 2020; 40(37).
48. Susana, R.C., Nagi, G.A. & Jae, K.L. Neuroinflammation Treatment via Targeted Delivery of Nanoparticles. Frontiers in Cellular Neuroscience. 2020; 14: 576037.
49. Sivakami, A., Sarankumar, R., & Vinodha, S. Introduction to Nanobiotechnology: Novel and Smart Applications. In: Paul K, ed. Bio-manufactured Nanomaterials. Switzerland, SW. Springer Nature; 2021: 1-22.